Can Upadacitinib Be Prescribed?
Yes, upadacitinib can be prescribed for multiple FDA-approved indications, but it is generally reserved as a second-line or later therapy after failure of other systemic treatments, with important safety considerations particularly in older adults and those with cardiovascular risk factors. 1, 2, 1
FDA-Approved Indications
Upadacitinib is approved for:
- Moderate-to-severe atopic dermatitis in patients who have failed other systemic therapies (immunosuppressants, corticosteroids, antimetabolites, injectable biologics) or when these are inadvisable 1
- Moderate-to-severe Crohn's disease 2, 3
- Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis 4
- Ulcerative colitis 5
Dosing by Indication
Atopic Dermatitis: 15 or 30 mg PO daily 1
- Higher doses (30 mg) demonstrate superior efficacy and may be preferred in patients with high disease burden or prior TNF antagonist failure
Crohn's Disease: Two maintenance dosing options available 2
- Higher maintenance doses preferred in patients with severe disease or prior biologic failure
Other conditions: Refer to disease-specific product labeling 6, 4
Positioning in Treatment Algorithm
Atopic Dermatitis
Upadacitinib is NOT first-line therapy. It should only be used after failure of other systemic therapies or when they are inadvisable 1. The medication demonstrates very high efficacy with rapid onset of action and was superior to dupilumab in head-to-head trials at higher doses (30 mg daily) 1.
Crohn's Disease
For biologic-naïve patients: Upadacitinib is classified as LOWER efficacy compared to biologics (infliximab, adalimumab, vedolizumab, ustekinumab, risankizumab, mirikizumab, guselkumab) 2
For biologic-experienced patients: Upadacitinib is classified as HIGHER efficacy and should be preferred over certolizumab or vedolizumab 2. It may be particularly useful in patients with prior TNF failure, intolerance, or contraindications 3.
Critical Safety Warnings
FDA Black Box Warnings
The FDA has applied class-wide warnings for JAK inhibitors regarding increased risk of 1, 4:
- Serious heart-related events (MACE)
- Cancer/malignancies
- Blood clots (venous thromboembolism)
- Death
These warnings are based on data from tofacitinib in rheumatoid arthritis patients ≥50 years with cardiovascular risk factors 1. However, this population differs substantially from most atopic dermatitis patients, and upadacitinib is a different JAK inhibitor with greater JAK-1 selectivity 1.
High-Risk Populations Requiring Caution
Patients over 65 years: The EMA recommends reserving upadacitinib for when no alternatives are available 3. Consider cardiovascular risk factors, smoking history, hypertension 2.
Pregnancy:
- Limited safety data exists 2
- Animal studies show teratogenic effects at therapeutic exposures 5
- Should generally be avoided in women contemplating pregnancy 2
- If exposure occurs, report to pregnancy surveillance program: 1-800-633-9110 5
Breastfeeding: Not recommended during treatment and for 6 days after last dose 5
Required Monitoring
Baseline Testing 1, 6
- Complete blood count with differential
- Liver enzymes
- Lipid panel
- Viral hepatitis screening
- Tuberculosis screening
- Pregnancy test (if applicable)
- Live vaccines should be administered BEFORE starting therapy
Ongoing Monitoring 1, 6
- CBC with differential: At baseline and per routine management after baseline
- Liver enzymes: At baseline and per routine management
- Lipids: 12 weeks after initiation
- The optimal frequency of continuous monitoring remains unclear 1
Contraindications and Drug Interactions
Avoid coadministration with:
- Potent immunosuppressants (azathioprine, cyclosporine) 7
- Other biologics 7
- Strong CYP3A4 inducers (e.g., rifampin) - may reduce efficacy 5
Dose adjustment needed with:
- Strong CYP3A4 inhibitors (e.g., ketoconazole): Reduce to 5 mg once daily 7
- Moderate-to-severe renal or hepatic impairment 7
Hold therapy during:
- Active serious infections 7
Common Pitfalls to Avoid
Do not use as first-line therapy in atopic dermatitis - this violates FDA approval and guideline recommendations 1
Do not prescribe without baseline screening for infections (TB, hepatitis), pregnancy, and laboratory abnormalities 1, 6
Do not ignore cardiovascular risk factors in older adults - consider alternative therapies in patients >50 years with CV risk factors 2, 1
Do not combine with other potent immunosuppressants or biologics 7
Special Clinical Scenarios
Perianal Crohn's disease: Upadacitinib may be beneficial based on post-hoc RCT analysis showing benefit across fistula endpoints 3
Extraintestinal manifestations:
- Peripheral arthropathy: Inferred efficacy from psoriatic arthritis data 3
- Axial spondyloarthropathy: Inferred efficacy from positive axial SpA data 3
Refractory cases: May require extended induction or dose escalation 2